论文部分内容阅读
用基因重组干扰素（ＩＦＮ－γ）对４１例骨髓增生异常综合征（ＭＤＳ）病人造血祖细胞的作用进行了体外观察，结果：①ＩＦＮ－γ体外对非血液病对照组病人的红系祖细胞（ＣＦＵ－Ｅ）和粒系祖细胞（ＣＦＵ－ＧＭ）无明显促增殖作用，而对ＭＤＳ病人的ＣＦＵ－Ｅ和ＣＦＵ－ＧＭ有明显促增殖作用。其作用呈剂量依赖型，在ＩＵ／ｍｌ时作用最小，１００Ｕ／ｍｌ时作用最强；②ＩＦＮ－γ对ＭＤＳ原ＣＦＵＥ和ＣＦＵ－ＧＭ增殖正常组加入ＩＦＮ－γ后集落数增加最明显，而对增殖明显减低组集落数无明显增加；③ＩＦＮ－γ对ＭＤＳ不同亚型病人ＣＦＵＥ和ＣＦＵ－ＧＭ作用不同，其中对转化中原始细胞增多的难治性贫血（ＲＡＥＢ－Ｔ）型病人有效率较高。
The effect of IFN-γ on hematopoietic progenitor cells in 41 patients with myelodysplastic syndrome (MDS) was observed in vitro. Results: ①IFN-γ in vitro in patients with non-hematological disease control group of patients with erythroid progenitor cells (CFU-E) and granulocyte-derived progenitor cells (CFU-GM) did not significantly promote the proliferation of MDS patients with CFU-E and CFU-GM significantly promote proliferation. The effect was dose-dependent at IU / ml and the effect was the strongest at 100U / ml; ② IFN-γ had the most obvious increase in the number of CFU-CFU and CFU-GM group (3) IFN-γ has different effect on CFUE and CFU-GM in patients with different subtypes of MDS, of which there is a high efficiency in refractory anemia (RAEB-T) patients with increased number of blasts .